Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy.
The goal of oncology is the individualization of patient care to optimize therapeutic responses and minimize toxicities. Achieving this will require noninvasive, quantifiable, and early markers of tumor response. Preclinical data from xenografted tumors using a variety of antitumor therapies have shown that magnetic resonance imaging (MRI)-measured mobility of tissue water (apparent diffusion coefficient of water, or ADCw) is a biomarker presaging cell death in the tumor. This communication tests the hypothesis that changes in water mobility will quantitatively presage tumor responses in patients with metastatic liver lesions from breast cancer. A total of 13 patients with metastatic breast cancer and 60 measurable liver lesions were monitored by diffusion MRI after initiation of new courses of chemotherapy. MR images were obtained prior to, and at 4, 11, and 39 days following the initiation of therapy for determination of volumes and ADCw values. The data indicate that diffusion MRI can predict response by 4 or 11 days after commencement of therapy, depending on the analytic method. The highest concordance was observed in tumor lesions that were less than 8 cm3 in volume at presentation. These results suggest that diffusion MRI can be useful to predict the response of liver metastases to effective chemotherapy.
Theilmann
Rebecca J
RJ
Department of Radiology, 1515 North Campbell Avenue, Tucson, AZ 85724-5024, USA.
Borders
Rebecca
R
Trouard
Theodore P
TP
Xia
Guowei
G
Outwater
Eric
E
Ranger-Moore
James
J
Gillies
Robert J
RJ
Stopeck
Alison
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D014408:Biomarkers, Tumor / Q000493:pharmacokinetics*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D018567:Breast Neoplasms, Male / Q000188:drug therapy / Q000473:pathology*; D038524:Diffusion Magnetic Resonance Imaging; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D014867:Water / Q000378:metabolism*
D014408:Biomarkers, Tumor; D014867:Water
Radiology. 1997 Sep;204(3):729-37
9280251
J Magn Reson Imaging. 1999 Aug;10(2):165-9
10441020
Cancer Res. 2001 Jul 1;61(13):4971-3
11431326
Neoplasia. 2002 May-Jun;4(3):255-62
11988845
Cancer Res. 1992 Nov 1;52(21):6025-30
1356623
Radiat Res. 1998 Jul;150(1):38-42
9650600
Radiology. 1997 Sep;204(3):739-44
9280252
Cancer Gene Ther. 1998 Mar-Apr;5(2):101-9
9570301
MAGMA. 1999 Mar;8(1):20-6
10383089
Lancet. 2002 Jul 27;360(9329):307-8
12147376
Cancer Res. 1996 Apr 15;56(8):1863-7
8620505
Gene Ther. 2000 Jun;7(12):1005-10
10871748
J Comput Assist Tomogr. 1996 Nov-Dec;20(6):905-13
8933789
J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36
11121466
Radiology. 1991 Aug;180(2):327-32
2068294
Neoplasia. 1999 Jun;1(2):113-7
10933044
Neoplasia. 2000 Jan-Apr;2(1-2):152-65
10933074
J Magn Reson Imaging. 1992 May-Jun;2(3):335-40
1627869
J Vasc Interv Radiol. 2000 Nov-Dec;11(10):1245-55
11099235
J Magn Reson Imaging. 1997 Nov-Dec;7(6):1040-7
9400847
Pancreas. 2000 Jul;21(1):69-76
10881935
Cancer Res. 1998 Sep 1;58(17):3791-9
9731486
Acad Radiol. 2001 Jan;8(1):42-7
11201456
Cell Death Differ. 2002 Dec;9(12):1307-10
12478467
Br J Cancer. 1996 Jan;73(1):61-4
8554985
Clin Cancer Res. 1997 Sep;3(9):1457-66
9815831